NEW CSRxP ANALYSIS: BIG PHARMA SPENDS THREE TIMES MORE ON PROFITS, ADVERTISING AND OVERHEAD THAN R&D
Sep 2, 2026
Breaking Down The “Big Pharma Dollar” Shows Brand Name Pharmaceutical… Read More
© 2026 CSRXP- All Rights Reserved
Articles/Reports
CSRxP ANALYSIS: PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS STILL 10 TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN
Jan 13, 2026
New Report Underscores How Brand Name Drug Companies Ride High on Egregious… Read More
CSRxP: FABRIZIO WARD SURVEY FINDS AMERICAN VOTERS OVERWHELMING HOLD BIG PHARMA COMPANIES RESPONSIBLE FOR HIGH DRUG PRICES
Feb 28, 2025
Voters Across the Political Spectrum Identify Pharmaceutical Company Profits… Read More
AMERICANS AGREE: CONGRESS MUST ACT TO HOLD BIG PHARMA ACCOUNTABLE AND LOWER DRUG PRICES
Nov 4, 2019
Solutions to Reform Medicare Part D, Increase Competition and Boost… Read More
New Study: Big Pharma Hikes Prices Without Improving Their Drugs
Oct 8, 2019
Unjustified Price Increases Cost Patients And Health Plans Billions Big Pharma… Read More
Going Boldly To The Bottom: Poll Finds Opinion Of Big Pharma Hits Record Low
Sep 3, 2019
Americans Have Negative View of Drug Makers by Two-to-One Margin… Read More
Big Pharma must be held accountable for insulin price crisis
Feb 23, 2019
By Sarah Gleich Saturday, Feb. 23, 2019 I have had diabetes since I was 5… Read More
RealClearHealth: Path Forward To Solving Out-Of-Control Drug Prices
Jan 31, 2019
Meaningful Reforms Have Already Taken Shape – Now It’s Up To Congress And… Read More
Avik Roy Unveils “The Competition Prescription”
May 16, 2017
Read "The Competition Prescription," a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down. Read More
Improving the Prescription Drug Market through Transparency, Competition, and Value
Aug 3, 2016
"Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here." Read More
How Do We Deal With Rising Drug Costs?
Apr 12, 2016
"There is no silver bullet here. We need to balance affordability, access and innovation whether or not Medicare is directly involved in price negotiations. We can only strike that balance when the market has transparency and competition, and purchasers can pay for value." Read More
Increasing Drug Prices Hurt Patients and Families
Mar 31, 2016
While it’s unconscionable that hedge fund pharmaceutical companies like Turing and Retrophin purchase treatments and suddenly raise prices, the current model in which drug companies raise prices year after year is just as bad for patients – and, frankly, unsustainable for our entire health care system. Read More